The US FDA has approved the world’s first digital pill, Abilify MyCite (aripiprazole tablets with sensor) of Otsuka Pharmaceutical, an antipsychotic that enables doctors to track whether the medicine is ingested by patients, the company said on November 14. The…
To read the full story
Related Article
- Sensor-Embedded Abilify Resubmitted to FDA
May 25, 2017
- Otsuka Aims to Resubmit NDA for Sensor-Embedded Abilify in US by Mid-Year
February 14, 2017
BUSINESS
- Leqembi FY2025 Global Sales Reach 88 Billion Yen: Eisai
May 1, 2026
- Rohto Files CMV Corneal Endotheliitis Drug in Japan
May 1, 2026
- Mochida Files in Japan for PAH Drug Tyvaso DPI
May 1, 2026
- Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
May 1, 2026
- 3D “Deeply Disappointed” by Toho Plan to Seek Defense Trigger Approval
May 1, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





